(Reuters Health) - The new anti-tuberculosis drug combination of bedaquiline, pretomanid and linezolid cures 90% of people with deadly drug-resistant TB if given for six months, researchers report in The New England Journal of Medicine.
Original Article: New TB drug regimen controls resistant disease in 9 of 10 cases: study